159 related articles for article (PubMed ID: 15845499)
1. Serologic responses to ACYW135 polysaccharide meningococcal vaccine in Saudi children under 5 years of age.
Al-Mazrou Y; Khalil M; Borrow R; Balmer P; Bramwell J; Lal G; Andrews N; Al-Jeffri M
Infect Immun; 2005 May; 73(5):2932-9. PubMed ID: 15845499
[TBL] [Abstract][Full Text] [Related]
2. Adolescent meningococcal serogroup A, W and Y immune responses following immunization with quadrivalent meningococcal A, C, W and Y conjugate vaccine: Optimal age for vaccination.
van Ravenhorst MB; van der Klis FRM; van Rooijen DM; Sanders EAM; Berbers GAM
Vaccine; 2017 Aug; 35(36):4753-4760. PubMed ID: 28647167
[TBL] [Abstract][Full Text] [Related]
3. Safety and immunogenicity of a meningococcal quadrivalent conjugate vaccine in five- to eight-year-old Saudi Arabian children previously vaccinated with two doses of a meningococcal quadrivalent polysaccharide vaccine.
Khalil M; Al-Mazrou Y; Findlow H; Chadha H; Bosch Castells V; Johnson DR; Borrow R
Clin Vaccine Immunol; 2012 Oct; 19(10):1561-6. PubMed ID: 22855388
[TBL] [Abstract][Full Text] [Related]
4. Induction of salivary antibody levels in Dutch adolescents after immunization with monovalent meningococcal serogroup C or quadrivalent meningococcal serogroup A, C, W and Y conjugate vaccine.
van Ravenhorst MB; den Hartog G; van der Klis FRM; van Rooijen DM; Sanders EAM; Berbers GAM
PLoS One; 2018; 13(4):e0191261. PubMed ID: 29672552
[TBL] [Abstract][Full Text] [Related]
5. Immunogenicity and Safety of a Quadrivalent Meningococcal ACWY-tetanus Toxoid Conjugate Vaccine 6 Years After MenC Priming as Toddlers.
Nolan T; Booy R; Marshall HS; Richmond P; Nissen M; Ziegler JB; Baine Y; Traskine M; Jastorff A; Van der Wielen M
Pediatr Infect Dis J; 2019 Jun; 38(6):643-650. PubMed ID: 31116180
[TBL] [Abstract][Full Text] [Related]
6. Dosage escalation, safety and immunogenicity study of four dosages of a tetravalent meninogococcal polysaccharide diphtheria toxoid conjugate vaccine in infants.
Rennels M; King J; Ryall R; Papa T; Froeschle J
Pediatr Infect Dis J; 2004 May; 23(5):429-35. PubMed ID: 15131466
[TBL] [Abstract][Full Text] [Related]
7. Comparative trial of the safety and immunogenicity of quadrivalent (A, C, Y, W-135) meningococcal polysaccharide-diphtheria conjugate vaccine versus quadrivalent polysaccharide vaccine in two- to ten-year-old children.
Pichichero M; Casey J; Blatter M; Rothstein E; Ryall R; Bybel M; Gilmet G; Papa T
Pediatr Infect Dis J; 2005 Jan; 24(1):57-62. PubMed ID: 15665711
[TBL] [Abstract][Full Text] [Related]
8. Preclinical immunogenicity and functional activity studies of an A+W meningococcal outer membrane vesicle (OMV) vaccine and comparisons with existing meningococcal conjugate- and polysaccharide vaccines.
Tunheim G; Arnemo M; Næss LM; Fjeldheim ÅK; Nome L; Bolstad K; Aase A; Mandiarote A; González H; González D; García L; Cardoso D; Norheim G; Rosenqvist E
Vaccine; 2013 Dec; 31(51):6097-106. PubMed ID: 24120679
[TBL] [Abstract][Full Text] [Related]
9. Meningococcal group C and w135 immunological hyporesponsiveness in african toddlers.
Findlow H; Sow S; Borrow R; Tapia M; Haidara FC; Akinsola AK; Idoko OT; Diallo F; Adegbola R; Tang Y; Parulekar V; Chadha H; Mabey L; Holme D; Townsend K; Chaumont J; Laforce FM; Kulkarni PS; Marchetti E; Viviani S; Hassan-King M; Preziosi MP
Clin Vaccine Immunol; 2011 Sep; 18(9):1492-6. PubMed ID: 21752951
[TBL] [Abstract][Full Text] [Related]
10. Immunoglobulin G subclass response to a meningococcal quadrivalent polysaccharide-diphtheria toxoid conjugate vaccine.
Findlow H; Southern J; Mabey L; Balmer P; Heyderman RS; Auckland C; Morris R; Miller E; Borrow R
Clin Vaccine Immunol; 2006 Apr; 13(4):507-10. PubMed ID: 16603620
[TBL] [Abstract][Full Text] [Related]
11. A randomized study comparing the safety and immunogenicity of a conjugate vaccine combination containing meningococcal group C and pneumococcal capsular polysaccharide--CRM197 with a meningococcal group C conjugate vaccine in healthy infants: challenge phase.
Riddell A; Buttery JP; McVernon J; Chantler T; Lane L; Bowen-Morris J; Diggle L; Morris R; Lockhart S; Pollard AJ; Cartwright K; Moxon ER
Vaccine; 2007 May; 25(19):3906-12. PubMed ID: 17368663
[TBL] [Abstract][Full Text] [Related]
12. Safety and immunogenicity of a booster dose of meningococcal (groups A, C, W, and Y) polysaccharide diphtheria toxoid conjugate vaccine.
Robertson CA; Greenberg DP; Hedrick J; Pichichero M; Decker MD; Saunders M
Vaccine; 2016 Oct; 34(44):5273-5278. PubMed ID: 27642132
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of De-O-acetylated meningococcal C polysaccharide-tetanus toxoid conjugate vaccine in infancy: reactogenicity, immunogenicity, immunologic priming, and bactericidal activity against O-acetylated and De-O-acetylated serogroup C strains.
Richmond P; Borrow R; Findlow J; Martin S; Thornton C; Cartwright K; Miller E
Infect Immun; 2001 Apr; 69(4):2378-82. PubMed ID: 11254596
[TBL] [Abstract][Full Text] [Related]
14. Primary and booster mucosal immune responses to meningococcal group A and C conjugate and polysaccharide vaccines administered to university students in the United Kingdom.
Zhang Q; Lakshman R; Burkinshaw R; Choo S; Everard J; Akhtar S; Finn A
Infect Immun; 2001 Jul; 69(7):4337-41. PubMed ID: 11401971
[TBL] [Abstract][Full Text] [Related]
15. Meningococcal serogroup C immunogenicity, antibody persistence and memory B-cells induced by the monovalent meningococcal serogroup C versus quadrivalent meningococcal serogroup ACWY conjugate booster vaccine: A randomized controlled trial.
van Ravenhorst MB; van der Klis FRM; van Rooijen DM; Knol MJ; Stoof SP; Sanders EAM; Berbers GAM
Vaccine; 2017 Aug; 35(36):4745-4752. PubMed ID: 28668575
[TBL] [Abstract][Full Text] [Related]
16. Safety and immunogenicity of meningococcus serogroup C conjugate vaccine administered as a primary or booster vaccination to healthy four-year-old children.
McVernon J; Maclennan J; Buttery J; Oster P; Danzig L; Moxon ER
Pediatr Infect Dis J; 2002 Aug; 21(8):747-53. PubMed ID: 12192163
[TBL] [Abstract][Full Text] [Related]
17. Immunogenicity of meningococcal ACYW135 polysaccharide vaccine in Saudi children 5 to 9 years of age.
Khalil M; Al-Mazrou Y; Balmer P; Bramwell J; Andrews N; Borrow R
Clin Diagn Lab Immunol; 2005 Oct; 12(10):1251-3. PubMed ID: 16210493
[TBL] [Abstract][Full Text] [Related]
18. Induction of immunologic memory by conjugated vs plain meningococcal C polysaccharide vaccine in toddlers: a randomized controlled trial.
MacDonald NE; Halperin SA; Law BJ; Forrest B; Danzig LE; Granoff DM
JAMA; 1998 Nov; 280(19):1685-9. PubMed ID: 9832000
[TBL] [Abstract][Full Text] [Related]
19. Comparison of antibody kinetics following meningococcal serogroup C conjugate vaccine between healthy adults previously vaccinated with meningococcal A/C polysaccharide vaccine and vaccine-naïve controls.
Borrow R; Southern J; Andrews N; Peake N; Rahim R; Acuna M; Martin S; Miller E; Kaczmarski E
Vaccine; 2001 Apr; 19(23-24):3043-50. PubMed ID: 11311998
[TBL] [Abstract][Full Text] [Related]
20. Use of saliva to monitor meningococcal vaccine responses: proposing a threshold in saliva as surrogate of protection.
van Ravenhorst MB; van der Klis FRM; van Rooijen DM; Sanders EAM; Berbers GAM
BMC Med Res Methodol; 2019 Jan; 19(1):1. PubMed ID: 30611213
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]